Canine coat pigmentation genetics: a review.

Anim Genet. February 2022;53(1):3-34.

L Brancalion¹, B Haase², C M Wade³

¹ Faculty of Science, School of Life and Environmental Sciences, University of Sydney, Camperdown, NSW, 2006, Australia.; ² Faculty of Science, School of Veterinary Science, University of Sydney, Camperdown, NSW, 2006, Australia.; ³ Faculty of Science, School of Life and Environmental Sciences, University of Sydney, Camperdown, NSW, 2006, Australia.

Abstract

Our understanding of canine coat colour genetics and the associated health implications is developing rapidly. To date, there are 15 genes with known roles in canine coat colour phenotypes. Many coat phenotypes result from complex and/or epistatic genetic interactions among variants within and between loci, some of which remain unidentified. Some genes involved in canine pigmentation have been linked to aural, visual and neurological impairments. Consequently, coat pigmentation in the domestic dog retains considerable ethical and economic interest. In this paper we discuss coat colour phenotypes in the domestic dog, the genes and variants responsible for these phenotypes and any proven coat colour-associated health effects.

Keywords

albinism; coat colour; deafness; dog; melanocyte; melanogenesis; pigmentation;

Article Tools:

Medline

Email to me

Comments:

Erratum In Anim Genet. 2022 Jun;53(3):474-475

Archives Highlights:

Feline acute patient physiologic and laboratory evaluation scores and other prognostic factors in cats with first-time diabetic ketoacidosis.
Median BG was significantly higher in non-survivors (431 mg/dL) compared with survivors (343 mg/dL) and BG predicted mortality. For every 1 mg/dL increase in BG, the odds of death increased by 1.004.

Efficacy, safety and interval from end of treatment to estrus in cats treated with an ultra-low dose megestrol acetate protocol for suppression of reproductive activity.
Twenty-eight queens were treated orally with 11.5 µg/kg/day of megestrol acetate (MA) for one to six months. MA suppressed reproductive function effectively in 27/28 queens. Transient mammary and uterine hyperplasia were detected in four (14 %) and three (11 %) queens, respectively, treated for more than four months, without associated clinical signs. Significant but reversible weight gain was observed in 85 % of the animals. The resumption of cyclicity occurred on average 6 weeks after the end of treatment but was influenced by the duration of treatment and seasonality.

Choose Your Own Adventure: Using Twine for Gamified Interactive Learning in Veterinary Anaesthesia.
Five interactive clinical cases were developed using Twine, simulating realistic anaesthesia scenarios with decision points and gamified elements, such as scoring systems and resource management. Feedback was highly positive; 90.8% found it effective for training, and 97.0% agreed it improved knowledge. User-friendliness was rated as "easy" or "very easy" by 94.6%. Regarding overall satisfaction, 96.7% of students described the workshop as "good" or "excellent".

Clinical characterization of a novel episodic ataxia in young working Cocker Spaniels.
The mean age at clinical onset was 4 months. Signs were acute and included episodic body swaying, titubation, cerebellar ataxia, wide-base stance, and hypermetria, all while mentation remained unaltered. Duration of episodes ranged from 30 minutes up to 24 hours, and their frequency varied from weekly to once every 5 months.

The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
Every day, rabbits produced a median of 75 g (range, 9 to 145 g) of feces, 226 fecal pellets (range, 12 to 412 pellets), and 151 mL (range, 5 to 420 mL) of urine. Metoclopramide, cisapride, pyridostigmine, and capromorelin had no effect on fecal production (both weight and number of pellets), food intake, urine production, or water intake compared to placebo at 24, 48, or 72 hours after administration.